Most Popular
1. It’s a New Macro, the Gold Market Knows It, But Dead Men Walking Do Not (yet)- Gary_Tanashian
2.Stock Market Presidential Election Cycle Seasonal Trend Analysis - Nadeem_Walayat
3. Bitcoin S&P Pattern - Nadeem_Walayat
4.Nvidia Blow Off Top - Flying High like the Phoenix too Close to the Sun - Nadeem_Walayat
4.U.S. financial market’s “Weimar phase” impact to your fiat and digital assets - Raymond_Matison
5. How to Profit from the Global Warming ClImate Change Mega Death Trend - Part1 - Nadeem_Walayat
7.Bitcoin Gravy Train Trend Forecast 2024 - - Nadeem_Walayat
8.The Bond Trade and Interest Rates - Nadeem_Walayat
9.It’s Easy to Scream Stocks Bubble! - Stephen_McBride
10.Fed’s Next Intertest Rate Move might not align with popular consensus - Richard_Mills
Last 7 days
US Presidential Election Year Stock Market Seasonal Trend - 29th Nov 24
Who controls the past controls the future: who controls the present controls the past - 29th Nov 24
Gold After Trump Wins - 29th Nov 24
The AI Stocks, Housing, Inflation and Bitcoin Crypto Mega-trends - 27th Nov 24
Gold Price Ahead of the Thanksgiving Weekend - 27th Nov 24
Bitcoin Gravy Train Trend Forecast to June 2025 - 24th Nov 24
Stocks, Bitcoin and Crypto Markets Breaking Bad on Donald Trump Pump - 21st Nov 24
Gold Price To Re-Test $2,700 - 21st Nov 24
Stock Market Sentiment Speaks: This Is My Strong Warning To You - 21st Nov 24
Financial Crisis 2025 - This is Going to Shock People! - 21st Nov 24
Dubai Deluge - AI Tech Stocks Earnings Correction Opportunities - 18th Nov 24
Why President Trump Has NO Real Power - Deep State Military Industrial Complex - 8th Nov 24
Social Grant Increases and Serge Belamant Amid South Africa's New Political Landscape - 8th Nov 24
Is Forex Worth It? - 8th Nov 24
Nvidia Numero Uno in Count Down to President Donald Pump Election Victory - 5th Nov 24
Trump or Harris - Who Wins US Presidential Election 2024 Forecast Prediction - 5th Nov 24
Stock Market Brief in Count Down to US Election Result 2024 - 3rd Nov 24
Gold Stocks’ Winter Rally 2024 - 3rd Nov 24
Why Countdown to U.S. Recession is Underway - 3rd Nov 24
Stock Market Trend Forecast to Jan 2025 - 2nd Nov 24
President Donald PUMP Forecast to Win US Presidential Election 2024 - 1st Nov 24
At These Levels, Buying Silver Is Like Getting It At $5 In 2003 - 28th Oct 24
Nvidia Numero Uno Selling Shovels in the AI Gold Rush - 28th Oct 24
The Future of Online Casinos - 28th Oct 24
Panic in the Air As Stock Market Correction Delivers Deep Opps in AI Tech Stocks - 27th Oct 24
Stocks, Bitcoin, Crypto's Counting Down to President Donald Pump! - 27th Oct 24
UK Budget 2024 - What to do Before 30th Oct - Pensions and ISA's - 27th Oct 24
7 Days of Crypto Opportunities Starts NOW - 27th Oct 24
The Power Law in Venture Capital: How Visionary Investors Like Yuri Milner Have Shaped the Future - 27th Oct 24
This Points To Significantly Higher Silver Prices - 27th Oct 24

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Can Biotech's Trump Bump Last?

Companies / BioTech Dec 03, 2016 - 12:36 PM GMT

By: TLSReport

Companies

In the weeks since Donald Trump's presidential election victory, the stock markets have ridden a wave into positive—and in the case of the Dow, record-breaking—territory. The so-called Trump Bump also sent biotech indices, flaccid for much of the year, up as much as 15%. With the election now nearly a month old, and hot-button issues such as drug pricing still in the press, industry watchers have begun to weigh in on what might happen in the biotech and pharma markets when Trump takes office.


Biotech stocks began their sharp climbs immediately after the elections, with the NASDAQ Biotechnology Index (NBI) climbing from the ~2,600 level to more than 3,000; it has since slid back into the ~2,800 range. The Life Sciences Report's 2016 Small-Cap Biotech Watchlist also surged, nibbling at positive territory before dropping to below breakeven as of Dec. 1.

As the Trump transition has progressed, experts have weighed in on what might have provoked the bump in biotech and pharma stocks, and what companies and their investors might expect going forward.

In an article for the Motley Fool published on Nov. 15, writer Cory Renauer cited several factors contributing to the biotech and pharma market boost. First, Hillary Clinton's defeat removed the immediate threat of government-imposed regulation of drug pricing. In addition, Trump's promise to go after the Affordable Care Act "with a sledgehammer" diverts attention away from drug pricing controversies.

Trump has also pledged to bring drug company profits stashed overseas back to the States. "If successful, the president-elect's plan to enact a one-time tax rate of just 10% on the repatriation of foreign profits could result in a nearly $100 billion U.S. drugmaker cash infusion," the Fool article states.

In addition, one of Trump's healthcare initiatives, as stated on his transition website, is to "reform the Food and Drug Administration, to put greater focus on the need of patients for new and innovative medical products." Though this mandate is "vague," the Fool article notes this could result in faster approvals for orphan drugs and generics.

FDA reform also carries risk, however. "Encouraging emotional patient advocates to force approvals for experimental drugs that haven't been proved safe and effective could put lives at risk, but it could also lower pre-approval development expenses. If the Trump administration takes clear steps in this direction, however misguided, it would continue lifting stock prices of biotechs developing rare-disease treatments," the article states.

Writing for Bloomberg, columnist Max Nisen noted on Nov. 22 that the jump in market values would enable companies to more easily access equity funding. But he advised taking advantage of the opening in the "fundraising window" quickly, because though "there's currently a market consensus Donald Trump's administration will be friendly to biotech, but there's no guarantee that feeling, or Trump's amity, will last."

Nisen also observed that biotech markets "have been unable to sustain a rally for any length of time this year, and the Trump Bump might be no different."

An article published by Reuters on Nov. 10 noted Trump's election could also lead to "an uptick in biotech M&A."

The article cites a "potential influx of foreign cash and improved stock valuations under the Trump administration" that could not only spark acquisition, but also "throw a lifeline to smaller biotech firms, which on average have only 11 months of cash left to finance their research, according to Thomson Reuters data, and have been hesitant to try to raise money during a weak equities market."

In an interview published on Nov. 22 in BioTuesdays, Jason Kolbert, senior biotechnology analyst with the Maxim Group, said Trump's "pro-business" mindset could be positive for biotech markets.

"In a Trump presidency, biotech and pharma industries should benefit and there is reason to believe that valuations will rally," Kolbert told the online publication. "We expect the outcome of this election to have a lasting impact on valuations and innovations, with things like R&D tax credits having an important long-term impact on company pipelines and productivity."

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
2) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
3) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
4) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their families are prohibited from making purchases and/or sales of those securities in the open market or otherwise during the up-to-four-week interval from the time of the interview or article until after it publishes.


© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in